Company Overview and News

0
Havells India Limited - Shareholders meeting

5h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
517354 HVLQY HAVELLS

0
Havells Q1 standalone net profit at Rs 210 crore

9h moneycontrol
Fast moving electronic goods (FMEG) company Havells posted a 73.3 percent YoY rise in its standalone net profit to Rs 210.4 crore for the first quarter beating estimates, on the back of a 39.5 percent rise in total income.
517354 HVLQY HAVELLS

0
Havells India Limited - Financial Result Updates

9h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
517354 HVLQY HAVELLS

0
Havells India Limited - Investor Presentation

9h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
517354 HVLQY HAVELLS

0
Wipro, Bajaj Auto, MCX, HDFC Life, Ceat results

2018-07-19 thehindubusinessline
Around two dozen companies including Atul, Bajaj Auto, Bajaj Holdings, Bata India, Capital Trust, Ceat, Chowgule Steamships, Diligent Media, HDFC Standard Life Insurance, Havells India, Infomedia Press, Kansai Nerolac Paints, L&T Finance Holdings, MCX, Nelco, Onward Technologies, Radhe Developers, Ramgopal Polytex, Sanwaria Consumer, Wipro and Zee Media Corporation will declare their quarterly numbers for the period ended June 2018 on Friday.
BAJAJ-AUTO RADHEDE CHOWGULSTM 517354 501833 HVLQY ONWARDTEC KNZAY 517536 532977 BATAINDIA 531273 KANSAINER 511505 HAVELLS INFOMEDIA CAPITALT 509069 500043 500165

0
Havells Q1 preview: Net profit seen rising 60.4% to Rs 194.8 crore

2018-07-19 moneycontrol
Fast moving electronic goods (FMEG) company Havells is expected to post a 60.4 percent rise in its standalone net profit to Rs 194.8 crore for the quarter ended June, according to a Reuters poll of equity analysts.
517354 HVLQY HAVELLS

0
Havells India Limited - Disclosure under SEBI Takeover Regulations

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
517354 HVLQY HAVELLS

0
Havells India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
517354 HVLQY HAVELLS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...